Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04267003 · ClinicalTrials.gov registry record · NA

Effects of Brain Stimulation on Cognition, Oscillations and GABA Levels in Schizophrenia

A NA study of Schizophrenia, sponsored by University of California, Davis.

Recruiting
Registry status
NA
Development phase
160
Enrollment target
1
Study location

NCT04267003: Recruiting NA study of Schizophrenia, sponsored by University of California, Davis.

NCT04267003 is a NA study of Schizophrenia that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 160 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04267003, a NA study of Schizophrenia, is actively recruiting participants, sponsored by University of California, Davis.

RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

People with schizophrenia often have problems with attention, learning and memory and other cognitive abilities that interfere with their work and school performance. Unfortunately, even our best treatments often do not significantly reduce these cognitive problems. The current study investigates whether or not delivering a very small electrical current to people's foreheads (called, transcranial direct current stimulation; (tDCS)) might improve functioning in the front part of the brain and reduce these cognitive problems in people with schizophrenia. tDCS is non-invasive and has been shown to improve cognitive functioning in some preliminary studies. The current study will investigate whether giving tDCS during a task is more effective than giving it during rest (Aim 1), whether delivery of tDCS to the front of the head is more effective than delivery to the back of the head (Aim 2), and whether tDCS delivery will alter levels of a major inhibitory neurotransmitter in the brain (GABA; Aim 3) that is important to cognitive functioning and may be disrupted in people with schizophrenia. Although this study is not intended to diagnose, cure or treat schizophrenia or any other disease, if results are positive it will encourage future large-scale studies to determine if tDCS can become an effective treatment for cognitive problems in people with schizophrenia.

Primary Outcome

Electrophysiological data recorded during completion of cognitive control tasks. We will measure oscillatory activity from 3-80 Hz.

Conditions Studied

Interventions

  • DEVICE Transcranial Direct Current Stimulation

Study Locations (1)

California

  • Imaging Research Center - Sacramento

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2020-01-09
Est. Completion 2026-08-31
Phase NA
University of California, Davis

657 total trials

What NCT04267003 shows while recruiting

NCT04267003 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (27% lower).

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Transcranial Direct Current Stimulation is the first listed.

NCT04267003 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04267003 about?

NCT04267003 is a clinical study titled "Effects of Brain Stimulation on Cognition, Oscillations and GABA Levels in Schizophrenia". People with schizophrenia often have problems with attention, learning and memory and other cognitive abilities that interfere with their work and school performance. Unfortunately, even our best treatments often do not significantly reduce these cognitive problems. The current study investigates wh...

What is the current status of trial NCT04267003?

This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2020-01-09. Estimated completion is 2026-08-31.

What conditions does trial NCT04267003 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT04267003?

The interventions under investigation include: Transcranial Direct Current Stimulation (DEVICE).

Who is sponsoring clinical trial NCT04267003?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04267003 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04267003's enrollment target sits among peer trials

160 102nd of 315 higher than 212 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04267003, the US trial registry maintained by the National Library of Medicine. NCT04267003 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.